XGN [NASD]
Exagen Inc.
Index- P/E- EPS (ttm)-1.70 Insider Own2.50% Shs Outstand16.99M Perf Week-22.86%
Market Cap81.52M Forward P/E- EPS next Y-1.79 Insider Trans0.00% Shs Float9.60M Perf Month-27.26%
Income-26.90M PEG- EPS next Q-0.55 Inst Own71.50% Short Float3.66% Perf Quarter-43.05%
Sales48.30M P/S1.69 EPS this Y-27.30% Inst Trans1.83% Short Ratio7.95 Perf Half Y-64.34%
Book/sh4.48 P/B1.02 EPS next Y-3.40% ROA-24.40% Target Price16.40 Perf Year-63.43%
Cash/sh5.06 P/C0.91 EPS next 5Y- ROE-35.50% 52W Range4.51 - 17.58 Perf YTD-60.53%
Dividend- P/FCF- EPS past 5Y-2.90% ROI-21.50% 52W High-71.50% Beta-
Dividend %- Quick Ratio8.70 Sales past 5Y32.90% Gross Margin57.40% 52W Low11.08% ATR0.75
Employees219 Current Ratio8.70 Sales Q/Q-1.90% Oper. Margin-58.10% RSI (14)36.50 Volatility21.01% 12.98%
OptionableYes Debt/Eq0.38 EPS Q/Q-26.00% Profit Margin-64.00% Rel Volume2.06 Prev Close4.59
ShortableYes LT Debt/Eq0.37 EarningsMay 11 AMC Payout- Avg Volume44.14K Price5.01
Recom1.50 SMA20-16.02% SMA50-28.29% SMA200-51.00% Volume19,587 Change9.15%
Oct-15-21Resumed Cowen Outperform $26
Apr-15-21Initiated Canaccord Genuity Buy $25
Nov-10-20Initiated KeyBanc Capital Markets Overweight $32
Oct-08-20Initiated BTIG Research Buy $18
Jun-02-20Resumed Cantor Fitzgerald Overweight $19 → $20
Oct-14-19Initiated William Blair Outperform
Oct-14-19Initiated Cowen Outperform $17
Oct-14-19Initiated Cantor Fitzgerald Overweight $18
May-16-22 04:05PM  
May-11-22 05:55PM  
04:06PM  
04:05PM  
May-10-22 10:45AM  
May-03-22 05:15PM  
May-01-22 12:00PM  
Apr-25-22 04:05PM  
Apr-20-22 04:05PM  
Apr-12-22 07:22AM  
Mar-30-22 08:25AM  
Mar-22-22 10:00PM  
05:25PM  
04:06PM  
04:05PM  
Mar-16-22 04:05PM  
Mar-09-22 05:35PM  
04:05PM  
Mar-08-22 04:05PM  
Mar-07-22 08:05AM  
Feb-24-22 05:40PM  
Feb-08-22 02:38PM  
Feb-02-22 04:05PM  
Jan-12-22 10:46AM  
Jan-09-22 12:00PM  
Nov-17-21 04:05PM  
Nov-11-21 08:30AM  
Nov-10-21 05:55PM  
04:05PM  
Nov-04-21 04:05PM  
Nov-03-21 03:01PM  
Oct-27-21 04:05PM  
08:25AM  
Oct-25-21 08:25AM  
Oct-21-21 04:05PM  
Oct-13-21 11:05AM  
Sep-13-21 04:15PM  
Aug-10-21 07:01AM  
Aug-09-21 06:35PM  
04:05PM  
Jul-30-21 08:25AM  
Jul-29-21 08:25AM  
Jul-26-21 04:06PM  
Jul-20-21 03:02PM  
Jul-15-21 07:04AM  
Jul-13-21 04:05PM  
Jun-22-21 09:25AM  
Jun-18-21 08:29AM  
May-24-21 04:05PM  
May-12-21 02:30AM  
May-11-21 04:05PM  
02:30PM  
May-04-21 04:05PM  
03:00PM  
May-03-21 08:25AM  
Apr-27-21 04:05PM  
Apr-16-21 09:45AM  
Mar-29-21 08:25AM  
Mar-25-21 04:15PM  
Mar-22-21 10:01PM  
04:05PM  
Mar-16-21 11:30PM  
05:25PM  
04:05PM  
02:30PM  
Mar-12-21 08:33AM  
Mar-09-21 12:30PM  
Mar-03-21 06:06AM  
Mar-02-21 08:00AM  
Feb-22-21 04:05PM  
Feb-15-21 08:58AM  
Feb-03-21 04:05PM  
Jan-22-21 07:22AM  
Jan-21-21 04:05PM  
Jan-10-21 06:00PM  
Jan-05-21 04:05PM  
Jan-04-21 04:05PM  
08:30AM  
Dec-11-20 08:35AM  
Nov-18-20 04:05PM  
Nov-16-20 08:25AM  
Nov-13-20 10:19AM  
Nov-10-20 10:01PM  
04:05PM  
02:45PM  
Nov-09-20 08:25AM  
Nov-02-20 08:25AM  
Oct-27-20 04:05PM  
Oct-21-20 04:05PM  
Oct-12-20 04:05PM  
Sep-29-20 08:25AM  
Sep-23-20 04:10PM  
Sep-22-20 03:57PM  
Sep-21-20 08:25AM  
Sep-03-20 04:05PM  
Aug-03-20 04:05PM  
Jul-30-20 04:25PM  
Jul-28-20 06:31PM  
07:00AM  
Jul-27-20 04:05PM  
Exagen Inc. develops and commercializes various testing products based on its Cell-Bound Complement Activation Products technology under the AVISE brand in the United States. It enables rheumatologists to enhance care for patients through the diagnosis, prognosis, and monitoring of systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company's products also comprise AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of eight autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE SLE Prognostic, a ten-biomarker panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with rapid and reliable results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody; AVISE Anti-CarP test, which identifies RA patients with severe disease; and AVISE PC4d to measure platelet- bound C4d. Further, the company offers AVISE SLE Monitor, a six-biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute and the AHN Autoimmunity Institute to develop novel patented biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Johnson Wendy S.DirectorSep 03Buy14.021,00014,0201,000Sep 07 08:25 AM
TULLIS JAMES L LDirectorAug 05Sale10.726,80072,8631,515,672Aug 06 04:15 PM
TULLIS JAMES L LDirectorAug 04Sale11.392,10023,9171,522,472Aug 04 06:29 PM
TULLIS JAMES L LDirectorAug 03Sale11.774,30050,6181,524,572Aug 04 06:29 PM
TULLIS JAMES L LDirectorAug 02Sale11.921,80021,4541,528,872Aug 04 06:29 PM
TULLIS JAMES L LDirectorJun 29Sale14.675,37978,9101,530,672Jun 29 05:10 PM
TULLIS JAMES L LDirectorJun 28Sale14.9810,858162,6961,536,051Jun 29 05:10 PM
TULLIS JAMES L LDirectorJun 25Sale16.038,763140,5031,546,909Jun 29 05:10 PM